Aberrant recombination involving the granzyme locus occurs in Atm−/− T-cell lymphomas
Ataxia telangiectasia (A-T) is an autosomal recessive disease caused by loss of function of the serine/threonine protein kinase ATM (ataxia telangiectasia mutated). A-T patients have a 250–700-fold increased risk of developing lymphomas and leukemias which are typically highly invasive and prolifera...
Saved in:
Published in: | Human molecular genetics Vol. 14; no. 18; pp. 2671 - 2684 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Oxford
Oxford University Press
15-09-2005
Oxford Publishing Limited (England) |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Ataxia telangiectasia (A-T) is an autosomal recessive disease caused by loss of function of the serine/threonine protein kinase ATM (ataxia telangiectasia mutated). A-T patients have a 250–700-fold increased risk of developing lymphomas and leukemias which are typically highly invasive and proliferative. In addition, a subset of adult acute lymphoblastic leukemias and aggressive B-cell chronic lymphocytic leukemias that occur in the general population show loss of heterozygosity for ATM. To define the specific role of ATM in lymphomagenesis, we studied T-cell lymphomas isolated from mice with mutations in ATM and/or p53 using cytogenetic analysis and mRNA transcriptional profiling. The analyses identified genes misregulated as a consequence of the amplifications, deletions and translocation events arising as a result of ATM loss. A specific recurrent disruption of the granzyme gene family locus was identified resulting in an aberrant granzyme B/C fusion product. The combined application of cytogenetic and gene expression approaches identified specific loci and genes that define the pathway of initiation and progression of lymphoreticular malignancies in the absence of ATM. |
---|---|
Bibliography: | ark:/67375/HXZ-P09TW6RW-0 To whom correspondence should be addressed. Tel: +1 8588127615; Fax: +1 8588127630; Email: cbarlow@braincellsinc.com local:ddi301 istex:064CC0DBC0C730571A5426F61E5DE67003C2F74A href:ddi301 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0964-6906 1460-2083 |
DOI: | 10.1093/hmg/ddi301 |